Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Inhibitor Development with Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia a: Final Results of the Nuprotect Study

Ri Liesner, Ellis J. Neufeld, MD

Blood (2019) 134 (Supplement_1): 903.

https://doi.org/10.1182/blood-2019-125520

Published: 2019

Journal Articles

Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Hemophilia a Patients

Feng Xue, MD, Jing Sun, MD, Yun Chen, MD, Xinsheng Zhang, MD, Haiyan Sun, MD, Yali Wang, PhD, Renchi Yang, MD

Blood (2019) 134 (Supplement_1): 4932.

https://doi.org/10.1182/blood-2019-128600

Published: 2019

Journal Articles

Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study

Johannes Oldenburg, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, MD, Tadashi Matsushita, Karina Meijer, Sabine Friedl, Martin Sanabria, Mark Reding

Blood (2019) 134 (Supplement_1): 4943.

https://doi.org/10.1182/blood-2019-128140

Published: 2019

Journal Articles

Lack of Inhibitor Development in the American Thrombosis and Hemostasis Network (ATHN)-2 Factor Switching Study: Preliminary Report of Primary Outcome

Robert F. Sidonio, Jr., MD MSc, Dunlei Cheng, PhD, Christine Guelcher, PPCNP-BC, Janna M. Journeycake, MD, Susan U Lattimore, Clifford Takemoto, MD, Michael D. Tarantino, MD, Crystal Watson, Ellis J. Neufeld, MD, Carol Fedor, RN

Blood (2019) 134 (Supplement_1): 1114.

https://doi.org/10.1182/blood-2019-128612

Published: 2019

Journal Articles

Incidence of Thrombocytopenia and Heparin Induced Thrombocytopenia in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Compared to Cardiopulmonary Bypass and the Limited Sensitivity of Pre-Test Probability Score

Deepa Jayakody Arachchillage, MD MRCP, FRCPath, Sanjay Khanna, Christophe Vandenbriele, Jonthan Dutton, Alex Rosenberg, MRCP, FCICM, FFICM, TC Aw, FRCA, Winston Banya, Maurizio Passariello, EDIC, Michael Laffan, DM, FRCP, FRCPath, Stephane Ledot, EDIC, MD, Brijesh Patel, MRCP, FRCA, FFICM , PhD

Blood (2018) 132 (Supplement 1): 2451.

https://doi.org/10.1182/blood-2018-99-119143

Published: 2018

Journal Articles

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Blood (2018) 132 (Supplement 1): 2472.

https://doi.org/10.1182/blood-2018-99-114518

Published: 2018

Journal Articles

Observational Study of Recombinant Factor-VIII-Fc, Eloctate, in Hemophilia Patients with and without Inhibitors

Patrick T. Ebbert, BS, Margaret V. Ragni, MD MPH, Frederico Xavier, MD MS, Lynn M. Malec, MD, Craig D. Seaman

Blood (2017) 130 (Supplement 1): 3689.

https://doi.org/10.1182/blood.V130.Suppl_1.3689.3689

Published: 2017

Journal Articles

Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (RIX-FP) in Previously Treated Adolescents/Adults with Hemophilia B: Long-Term Efficacy and Safety from an Ongoing Phase 3b Extension Clinical Trial

Ingrid Pabinger, MD, Elena Santagostino, Andres Brainsky, MD, Jerry S. Powell, MD, Yanyan Li, PhD, Wilfried Seifert, PhD

Blood (2017) 130 (Supplement 1): 3690.

https://doi.org/10.1182/blood.V130.Suppl_1.3690.3690

Published: 2017

Journal Articles

Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (RIX-FP) in Previously Treated Children < 12 Years of Age with Hemophilia B: Long-Term Efficacy and Safety from an Ongoing Phase 3b Extension Clinical Trial

Gili Kenet, MD, Andres Brainsky, MD, Jerry S. Powell, MD, Yanyan Li, PhD, Wilfried Seifert, PhD

Blood (2017) 130 (Supplement 1): 2370.

https://doi.org/10.1182/blood.V130.Suppl_1.2370.2370

Published: 2017

Journal Articles

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Yesim G. Dargaud, MDPhD, Robert Klamroth, Luminita Rusen, MD, Jerzy Windyga, MD, Johann Bichler, PhD, Sigurd Knaub, Claude Negrier, MD

Blood (2016) 128 (22): 1410.

https://doi.org/10.1182/blood.V128.22.1410.1410

Published: 2016

Journal Articles

Profiling and Comparing the Immunogenicity of a Novel Single-Chain FVIII Molecule (rVIII-SingleChain) for the Treatment of Hemophilia a

Eugene Maraskovsky, PhD, Anne Verhagen, PhD, Huy Huynh, BS, Adriana Baz Morelli, PhD, Stefan Schmidbauer, BS, Sabine Zollner, PhD, Jerry S. Powell, Katie St Ledger, Alex Veldman, MD, Marco Hofmann, MS

Blood (2016) 128 (22): 4960.

https://doi.org/10.1182/blood.V128.22.4960.4960

Published: 2016

Journal Articles

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

Frank Michael Horling, PhD, Peter Allacher, PhD, Herwig Koppensteiner, PhD, Werner Engl, PhD Cstat, Fritz Scheiflinger, PhD, Brigitt E. Abbuehl, MD, Birgit M Reipert, PhD

Blood (2016) 128 (22): 2594.

https://doi.org/10.1182/blood.V128.22.2594.2594

Published: 2016

Journal Articles

An Evaluation of Safety with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of 243 Patients with Hemophilia a

Werner Engl, PhD Cstat, Lisa Patrone, PhD, Dyck-Jones Jacqueline, PhD, Srilatha D. Tangada, PhD, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 3801.

https://doi.org/10.1182/blood.V128.22.3801.3801

Published: 2016

Journal Articles

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Blood (2016) 128 (22): 327.

https://doi.org/10.1182/blood.V128.22.327.327

Published: 2016

Journal Articles

Perioperative Efficacy of an Extended Half-Life, Pegylated, Full-Length, Recombinant Factor VIII (BAX 855) in Individual Procedures

Brigitte Brand, Ralph A. Gruppo, MD, Tung T. Wynn, Laimonas Griskevicius, Maria Fernanda Lopez Fernandez, Thomas Dvorak, Lisa Patrone, Brigitt E. Abbuehl

Blood (2015) 126 (23): 2299.

https://doi.org/10.1182/blood.V126.23.2299.2299

Published: 2015

Journal Articles

Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855)

Marilyn J. Manco-Johnson, MD, Alice D. Ma, MD, Robert Klamroth, Werner Engl, Lorena Griparic, PhD, Jacqueline A Dyck-Jones, PhD, Brigitt E. Abbuehl

Blood (2015) 126 (23): 2300.

https://doi.org/10.1182/blood.V126.23.2300.2300

Published: 2015

Journal Articles

Characteristics of Patients without Bleeding in a Pivotal Trial of Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A

Alice D. Ma, MD, Robert Klamroth, Marilyn J. Manco-Johnson, MD, Werner Engl, Jacqueline A Dyck-Jones, PhD, Brigitt E. Abbuehl

Blood (2015) 126 (23): 1105.

https://doi.org/10.1182/blood.V126.23.1105.1105

Published: 2015

Journal Articles

An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia a

Pratima Chowdary, Barbara Konkle, MD, Tadashi Matsushita, MD PhD, Werner Engl, Lisa Patrone, Brigitt E. Abbuehl

Blood (2015) 126 (23): 3522.

https://doi.org/10.1182/blood.V126.23.3522.3522

Published: 2015

Journal Articles

Changes in Annualized Bleeding Rate over Time and Relationship with Dosing of Turoctocog Alfa during the guardian™ Program

Margareth Ozelo, MD PhD, Dragana Janic, Irina Matytsina, Andrea Landorph, Niels Zeuthan, Elena Santagostino

Blood (2014) 124 (21): 2850.

https://doi.org/10.1182/blood.V124.21.2850.2850

Published: 2014

Journal Articles

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

Elena Santagostino, MD PhD, Iris C. Jacobs, MD, Christine Voigt, PhD, Annettee Feussner, PhD, Tharin Limsakun, PhD

Blood (2014) 124 (21): 1491.

https://doi.org/10.1182/blood.V124.21.1491.1491

Published: 2014

NARROW

Inhibitor Development with Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia a: Final Results of the Nuprotect Study

Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Hemophilia a Patients

Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study

Lack of Inhibitor Development in the American Thrombosis and Hemostasis Network (ATHN)-2 Factor Switching Study: Preliminary Report of Primary Outcome

Incidence of Thrombocytopenia and Heparin Induced Thrombocytopenia in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Compared to Cardiopulmonary Bypass and the Limited Sensitivity of Pre-Test Probability Score

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Observational Study of Recombinant Factor-VIII-Fc, Eloctate, in Hemophilia Patients with and without Inhibitors

Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (RIX-FP) in Previously Treated Adolescents/Adults with Hemophilia B: Long-Term Efficacy and Safety from an Ongoing Phase 3b Extension Clinical Trial

Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (RIX-FP) in Previously Treated Children < 12 Years of Age with Hemophilia B: Long-Term Efficacy and Safety from an Ongoing Phase 3b Extension Clinical Trial

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Profiling and Comparing the Immunogenicity of a Novel Single-Chain FVIII Molecule (rVIII-SingleChain) for the Treatment of Hemophilia a

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

An Evaluation of Safety with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of 243 Patients with Hemophilia a

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Perioperative Efficacy of an Extended Half-Life, Pegylated, Full-Length, Recombinant Factor VIII (BAX 855) in Individual Procedures

Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855)

Characteristics of Patients without Bleeding in a Pivotal Trial of Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A

An Integrated Analysis of Long Term Safety of an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia a

Changes in Annualized Bleeding Rate over Time and Relationship with Dosing of Turoctocog Alfa during the guardian™ Program

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only